Signifor LAR Signifor

Support Icon

Contact a Recordati Rare Diseases Representative

Target the source

SIGNIFOR LAR is a second generation SSA designed to reduce long-term overproduction of GH and IGF-1.1,2

SIGNIFOR LAR is a second-generation somatostatin analog (SSA) designed to reduce overproduction of growth hormone (GH) and insulin-like growth factor 1 (IGF-1) to help achieve biochemical normalization.1,2


Icon representing HCP

SIGNIFOR LAR is a long-acting intramuscular injection given by a trained healthcare professional once every 4 weeks (28 days).1

Resources for you
and your patient

GH=growth hormone; IGF-1=insulin-like growth factor 1; SST=somatostatin.

References: 1. SIGNIFOR LAR (pasireotide) Injection [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2019. 2. Christofides EA. Patient Prefer Adherence. 2016;10:1217-1225.

Indications and Usage

SIGNIFOR LAR (pasireotide) is a somatostatin analog indicated for the treatment of:

Important Safety Information

Warnings and Precautions

Indications and Usage

SIGNIFOR LAR (pasireotide) is a somatostatin analog indicated for the treatment of:

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Females and Males of Reproductive Potential